Ftse Mib
32.921,18
0,78%
DAX
18.072,65
0,29%
S&P 500
5.440,60
0,17%
NASDAQ
17.724,56
0,20%
Bitcoin
65.407,59
-1,86%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Salarius Pharmaceuticals Inc (SLRX) Salarius Pharmaceuticals Inc (SLRX) Notizie

SLRX

Salarius Pharmaceuticals (SLRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLRX
DataOraFonteTitoloSimboloCompagnia
17/06/202414:11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202414:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
17/06/202414:00GlobeNewswire Inc.Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202414:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/05/202422:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
22/03/202421:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202414:00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesNASDAQ:SLRXSalarius Pharmaceuticals Inc
16/01/202414:00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
03/01/202414:30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNASDAQ:SLRXSalarius Pharmaceuticals Inc
07/11/202314:30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/10/202321:57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/08/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/07/202314:30GlobeNewswire Inc.Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202314:00GlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/06/202312:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SLRXSalarius Pharmaceuticals Inc
07/06/202313:28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/06/202323:02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
26/05/202323:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322:34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322:05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/05/202314:00GlobeNewswire Inc.Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/05/202314:00GlobeNewswire Inc.Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
09/05/202314:00GlobeNewswire Inc.FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing SarcomaNASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202314:30GlobeNewswire Inc.Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202314:05Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/05/202314:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
20/04/202314:30GlobeNewswire Inc.Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual MeetingNASDAQ:SLRXSalarius Pharmaceuticals Inc
04/04/202322:02GlobeNewswire Inc.Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational ConferenceNASDAQ:SLRXSalarius Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLRX

La tua Cronologia

LSE
QIH
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network